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1  |  INTRODUC TION
There is emerging interest in the effect of COVID-19 on glucose ho-
meostasis, with some suggesting that COVID-19 may be a uniquely 
diabetogenic virus.1 Observations advanced to support this hy-
pothesis include anecdotal reports of high insulin requirements in 
patients with severe COVID-19.2–4 However, to date there has been 
no longitudinal study of patients with COVID-19 to empirically as-
sess insulin requirements. We sought to address this deficiency by 
comparing insulin requirements in patients admitted to intensive 
care with severe COVID-19 to a historical control group with severe 
non-COVID-19 viral pneumonitis.
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quirements. It has been proposed that this may be driven by a direct diabetogenic ef-
fect	of	the	virus	that	is	unique	to	SARS-CoV-2,	but	evidence	to	support	this	is	limited.	
To explore this, we compared insulin requirements in patients with severe COVID-19 
and non-COVID-19 viral pneumonitis.
Methods: This is a retrospective cohort study of patients with severe COVID-19 ad-
mitted	to	our	intensive	care	unit	between	March	and	June	2020.	A	historical	control	
cohort of non-COVID-19 viral pneumonitis patients was identified from routinely col-
lected audit data.
Results: Insulin requirements were similar in patients with COVID-19 and non-
COVID-19 viral pneumonitis after adjustment for pre-existing diabetes and severity 
of respiratory failure.
Conclusions: In this single-centre study, we could not find evidence of a unique diabe-
togenic effect of COVID-19. We suggest that high insulin requirements in this disease 
relate to its propensity to cause severe respiratory failure in patients with pre-existing 
metabolic disease.
K E Y W O R D S
COVID-19, diabetes, insulin resistance, stress hyperglycaemia
2 of 4  |     LOCKHART eT AL.
2  |  RESE ARCH DESIGN AND METHODS
2.1  |  Case identification
Patients	 admitted	 to	 ICU	 in	 Addenbrooke's	 Hospital,	 Cambridge,	
with	 a	 positive	 SARS-CoV-2	 test	 were	 identified.	 Patients	 were	
deemed to have COVID-19 pneumonitis and included in the study 
if	they	were	SARS-CoV-2	positive	and	were	treated	for	respiratory	
failure that was attributed to COVID-19 pneumonitis by the treating 
team during their ICU stay.
The non-COVID-19 viral pneumonitis cohort was identified from 
the	ICU’s	routinely	collected	audit	data	from	2014	to	2019.	Patients	
admitted with a diagnosis of viral pneumonia recorded as their pri-
mary, secondary or ultimate reason for admission to intensive care 
were included in the analysis.
All	eligible	participants	were	included.
2.2  |  Data collection
Data collection was undertaken manually from electronic medical 
records by trained, clinical investigators. Blood glucose data were 
collected using proprietary analytics software, QlikView. Further 
detail	is	available	in	Appendix	S1.
2.3  |  Matching
Patients admitted with COVID-19 pneumonitis were matched ac-
cording to diabetes status and level of respiratory support received 
in a 1:1 ratio to a historical control cohort of patients admitted to 
ICU with non-COVID-19 viral pneumonitis. Further data are avail-
able	in	Appendix	S1.




tients treated for severe COVID-19 within our intensive care unit 
(Appendix	S1:	Figure	S1).	In	univariate	linear	regression	analysis,	BMI,	
pre-existing type 1 or type 2 diabetes and severity of respiratory 
failure assessed by ordinal scale (0—self ventilating, 1—mechanical 
ventilation, 2—neuromuscular blockade, 3—nebulized epoprostenol, 
4—prone ventilation, 5—extracorporeal membrane oxygenation) 
were all associated with insulin dose when analysed by the average 
dose across the whole ICU stay or by the highest cumulative insulin 
dose	over	a	24-h	period	(Appendix	S1:	Table	S1).
To determine if the observed insulin requirements were a 
unique feature of COVID-19, we examined insulin requirements in 
46 patients admitted to our ICU with a diagnosis of non-COVID-19 
viral pneumonitis between 2014 and 2019. 89% of the non-
COVID-19 cohort had a confirmed viral isolate consistent with viral 
pneumonia. Five patients included in the analysis did not have any 
relevant positive virology related to their ICU admission but were 
diagnosed with viral pneumonitis on clinical grounds while two pa-
tients had more than 1 virus identified that could have explained 
their	 symptoms	 (Appendix	 S1:	 Table	 S2	 for	 a	 breakdown	 of	 viral	
isolates). Insulin requirements were higher in patients with COVID-
19 versus non-COVID-19 viral pneumonitis while mean glycaemic 
indices	were	comparable	in	both	groups	(Figure	1A,B	and	Appendix	
S1:	Figure	S2A,B).	However,	the	groups	were	poorly	balanced	with	
respect to diabetes status and requirement for respiratory salvage 
therapies	 (Appendix	 S1:	 Table	 S3),	 and	multiple	 regression	 analy-
sis did not identify any association between COVID-19 and insu-
lin dose after adjustment for pre-existing diabetes and severity of 
respiratory failure (Table 1). While severity of respiratory failure 
was independently associated with insulin requirement, we did not 
find	a	similar	relationship	for	vasopressor	use	or	APACHE	II	score	
(data not shown). When COVID-19 and non-COVID-19 viral pneu-
monitis patients were matched (1:1, N = 36 per group) by the level 
of respiratory support required and pre-existing diabetes status, 
the proportion of patients requiring insulin (COVID-19: 41%, non-
COVID-19: 49%) and insulin dose was similar in those who were 
treated	with	insulin	(Figure	1C,D	and	Appendix	S1:	Figure	S2C,D).	
We acknowledge that diabetes is a heterogenous condition with 
different intensity of treatment and adequacy of glycaemic control 
and controlling for it as a single variable is limited. However, the 
number of patients with type 1 diabetes in COVID-19 and non-
COVID-19 was the same and the treatments used in type 2 diabetes 
COVID-19 and non-COVID-19 viral pneumonitis are not dissimilar 
(Appendix	 S1:	 Table	 S4).	Unfortunately,	 a	 large	proportion	of	 pa-
tients	in	our	study	did	not	have	pre-morbid	HbA1c values on records 
at our institution therefore precluding meaningful comparison of 
pre-morbid glycaemic control.
Finally, we sought to determine if the insulin requirements 
observed in patients with COVID-19 resolved in convalescence. 
Diabetes therapies used in patients with COVID-19 and non-
COVID-19	viral	pneumonitis	are	summarized	in	Appendix	S1:	Table	
S4.	We	had	information	on	discharge	medication	in	61/62	patients	
who survived to hospital discharge. Of these patients, 39 required 
insulin while in ICU but on discharge only five patients were dis-
charged from hospital on subcutaneous insulin, four of whom were 
on insulin prior to admission. The one patient commenced on insulin 
had type 2 diabetes prior to admission managed with oral therapy, 
and insulin was discontinued soon after discharge when they were 
readmitted with hypoglycaemia. There was no initiation or escala-
tion in oral hypoglycaemic agents in the cohort; however, we can-
not	comment	on	the	adequacy	of	glycaemic	control.	Similar	findings	
from a smaller cohort have recently been reported.3
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4  |  DISCUSSION
We report here, to the best of our knowledge, the first longitudinal 
assessment of glycaemia and insulin requirements in patients who 
are critically ill with COVID-19. Our data suggest that high insulin 
requirements observed in patients with severe COVID-19 are re-
lated to the severity of respiratory failure and pre-existing diabe-
tes	mellitus	rather	than	a	direct	diabetogenic	effect	of	SARS-CoV-2.	
Therefore, there is currently no rationale to adopt novel strategies or 
different glycaemic thresholds to manage hyperglycaemia in COVID-
19 compared to other viral pneumonias and several reviews have 
outlined practical approaches to the management of hyperglycaemia 
in COVID-19.2,4,5 Moreover, the comparable insulin requirements in 
COVID-19 and non-COVID-19 viral pneumonitis when severity of 
illness and pre-existing diabetes are accounted for argue against a 
direct	 action	of	 SARS-CoV-2	on	 the	 pancreatic	β-cell as the likely 
cause of hyperglycaemia in COVID-19, as has been suggested pre-
viously.6 In addition, our data suggest that the hyperglycaemia 
observed in patients with COVID-19 is transient and resolves in 
convalescence and leads us to caution studies describing new-onset 
diabetes in patients with COVID-19 based on cross-sectional blood 
glucose measurements.7
Our findings are complementary to a recent analysis that exam-
ined time in target glucose range in patients admitted to ICU with 
COVID-19. The authors found that ventilator use, neuromuscular 
blockade and use of high-flow nasal oxygen all predicted poor glycae-
mic control.8 Interestingly, this study compared glycaemia and insulin 
requirements in 93 COVID-19 patients to all (N = 469) contempora-
neous ICU admissions (for any reason) without COVID-19 and found 
that COVID-19 patients had poorer glycaemic control and higher 
insulin requirements. However, the COVID-19 group required much 
more respiratory support compared to the non-COVID-19 group and 
the authors did not make any attempt to adjust for this difference.
While preparing our paper for publication, two separate analy-
ses have suggested that insulin therapy in hospital may be associated 
with increased mortality in patients with type 2 diabetes.9,10 One of 
these reports has been widely interpreted as supporting the supposi-
tion that insulin therapy is detrimental in COVID-19.11 We would take 
the view that these findings represent reverse causation—whereby 
those with severe illness require insulin to treat stress hyperglycae-
mia.	An	alternative	explanation	is	that	the	optimal	glycaemic	targets	
F I G U R E  1 Insulin	requirements	of	
patients admitted to ICU with COVID-19 
and	non-COVID-19	viral	pneumonitis.	(A)	
Tukey box plots of maximum cumulative 
insulin requirements in a single day in 
the complete cohort, p = .003 by Mann-
Whitney U test. (B) Tukey box plots 
of mean daily insulin dose day in the 
complete cohort, p = .003 by Mann-
Whitney U test. (C) Tukey box plots of 
maximum cumulative insulin requirements 
in a single day in the matched cohort, 
p = .46 by Wilcoxon signed rank test. 
(D) Tukey box plots of mean daily insulin 
dose day in the matched cohort, p = .52 
by Wilcoxon signed rank test. For clarity 
only insulin dose for patients receiving 
insulin plotted (ie no zero values plotted) 
but statistical tests are performed on the 

























































































TA B L E  1 Correlation	coefficients	±	standard	error,	multiple	R-
squared and p-values from multivariable linear regression analysis 
of maximum insulin requirement in a single day and mean insulin 
requirements per day, following a square root transformation
Beta p-Value
Maximum insulin requirement in a single day, R2 = .47
COVID-19 0.10	±	0.71 .89
Diabetes mellitus 4.66	±	0.75 <.001
Respiratory support 1.41	±	0.21 <.001
Mean insulin requirements per day, R2 = .50
COVID-19 0.20	±	0.50 .71
Diabetes mellitus 5.60	±	1.05 <.001
Respiratory support 1.64	±	0.26 <.001
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in patients with type 2 diabetes and severe illness are unclear, and 
some observational analyses have suggested more liberal targets in 
patients with type 2 diabetes may be preferable—a hypothesis being 
examined	by	the	LUCID	Randomized	Controlled	Clinical	Trial.12
It is interesting to speculate on the pathophysiological mecha-
nisms linking severity of respiratory failure to insulin requirements 
in viral pneumonitis. It is well established that acute illness causes 
stress hyperglycaemia and the production of pro-inflammatory cy-
tokines and counterregulatory hormones are likely key players in this 
process.13 What is less well established is that severity of respiratory 
failure specifically is associated with insulin resistance and stress hy-
perglycaemia. Causative mechanisms likely overlap but some patho-
genic processes may be specific to tissue dysoxia. Examining insulin 
requirements and glycaemia treated with liberal and conservative 
oxygen strategies in randomized controlled trials may be instructive 
in this regard.
Our analysis is limited by its relatively small sample size and its 
single-centre nature. Further determination of the specific effects of 
COVID-19 infection as opposed to the effects of general critical ill-
ness will require collection of data from larger, well-matched cohorts 
with other precipitating causes of stress hyperglycaemia.
It should be noted that we cannot exclude the existence of rare 
hyperglycaemic	syndromes	triggered	by	SARS-CoV-2	infection.	For	
example,	 our	 study	 cannot	 inform	 the	 aetiological	 role	 of	 SARS-
CoV-2 infection in autoimmune diabetes as has been studied in 
larger epidemiological analyses.14–16	 Large,	 registry-based	 studies	
(eg	COVIDIAB	 registry)	with	prolonged	 follow-up	will	 be	 required	
to study this and to determine the long-term effects of COVID-19 
infection on glucose metabolism more broadly.
In conclusion, high insulin requirements in severe COVID-19 
likely relate to the severity of respiratory failure and the high prev-
alence of metabolic disease in patients with severe illness. When 
these factors are accounted for, insulin requirements are compara-
ble to that seen in non-COVID-19 viral pneumonitis.
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